Viridian Therapeutics, Inc.\DE (VRDN) Current Assets (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Current Assets of $784.7 million for Q1 2026, up 19.4% year-over-year from $657.2 million in Q1 2025, and down 12.24% quarter-over-quarter from $894.2 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Current Assets (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Current Assets history runs 14 years deep, the most recent figure standing at $784.7 million for Q1 2026.
- In Q1 2026, Current Assets rose 19.4% year-over-year to $784.7 million; the TTM figure through Mar 2026 stood at $784.7 million (up 19.4% YoY), while the FY2025 annual figure was $894.2 million, up 21.09% from the prior year.
- Current Assets for Q1 2026 stood at $784.7 million, down from $894.2 million in the prior quarter.
- The five-year high for Current Assets was $894.2 million in Q4 2025, with the low at $166.2 million in Q2 2022.
- The 5-year median for Current Assets is $571.9 million (2025), against an average of $526.7 million.
- The sharpest annual moves came in 2023 and 2024: Current Assets retreated 25.96% in 2023, then soared 136.96% in 2024.
- Viridian Therapeutics, Inc.\DE's Current Assets stood at $431.2 million in 2022, then gained by 12.83% to $486.5 million in 2023, then surged by 51.8% to $738.5 million in 2024, then rose by 21.09% to $894.2 million in 2025, then decreased by 12.24% to $784.7 million in 2026.
- Business Quant data shows VRDN's Current Assets at $784.7 million in Q1 2026, $894.2 million in Q4 2025, and $571.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 1.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.08 Bn |
| Mar 31, 2026 | 784.74 Mn |
| Dec 31, 2025 | 894.23 Mn |
| Sep 30, 2025 | 571.91 Mn |
| Jun 30, 2025 | 578.75 Mn |
| Mar 31, 2025 | 657.24 Mn |
| Dec 31, 2024 | 738.46 Mn |
| Sep 30, 2024 | 767.36 Mn |
| Jun 30, 2024 | 581.66 Mn |
| Mar 31, 2024 | 626.82 Mn |
| Dec 31, 2023 | 486.48 Mn |
| Sep 30, 2023 | 323.84 Mn |
| Jun 30, 2023 | 346.33 Mn |
| Mar 31, 2023 | 382.60 Mn |
| Dec 31, 2022 | 431.17 Mn |
| Sep 30, 2022 | 437.36 Mn |
| Jun 30, 2022 | 166.15 Mn |
| Mar 31, 2022 | 179.39 Mn |
| Dec 31, 2021 | 200.16 Mn |
| Sep 30, 2021 | 217.94 Mn |